Calcium acetate/magnesium carbonate - Fresenius Medical Care

Drug Profile

Calcium acetate/magnesium carbonate - Fresenius Medical Care

Alternative Names: OsvaRen; Rephoren

Latest Information Update: 14 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fresenius Medical Care
  • Class Acetates; Elements; Inorganic chemicals; Small molecules
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 01 Jun 2015 Fresenius Medical Care completes a phase II/III trial in Hyperphosphataemia in Germany (NCT02027662)
  • 01 Jan 2014 Phase-II/III clinical trials in Hyperphosphataemia in Germany (PO, granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top